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BACKGROUND: A cointervention in a randomized clinical trial (RCT) is medical care given in addition to the tested intervention. 
If cointerventions are unbalanced between trial arms, the results may be biased. We hypothesized that cointerventions would 
be more adequately reported in RCTs without full blinding or at risk of bias.
METHODS AND RESULTS: To describe the reporting of cointerventions and to evaluate the factors associated with their reporting, 
we did a systematic search of all RCTs evaluating pharmacological interventions on cardiovascular outcomes published in 5 
high- impact journals. The reporting of cointerventions, blinding, and risk of bias were extracted and evaluated independently 
by 2 reviewers (E.M., L.A.). Cointerventions were inadequately reported in 87 of 123 RCTs (70.7%), with 56 (45.5%) providing 
no information on cointerventions and 31 (25.2%) providing only partial information. Of the RCTs, 52 (42.3%) had inadequate 
blinding of participants and/or personnel and 63 (51.2%) of the RCTs were judged at risk of bias. In univariable analysis, the 
reporting of cointerventions was not associated with blinding of participants and/or personnel (odds ratio [OR], 1.04; 95% CI, 
0.47–2.27 for adequately versus inadequately blinded trials) or with risk of bias (OR, 1.47; 95% CI, 0.67–3.21 for at low risk 
of bias versus trials at risk of bias). In multivariable analysis, only a follow- up of <1 month was associated with the adequate 
reporting of cointerventions (OR, 3.63; 95% CI, 1.21–10.91).
CONCLUSIONS: More than two- thirds of recent major cardiovascular trials did not adequately report cointerventions. The quality 
of reporting was not better among trials that were not fully blinded or at risk for bias.
REGISTRATION: URL: https://www.crd.york.ac.uk/PROSP ERO/. Unique identifier: CRD42018106771. 
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Because randomized clinical trial (RCT) outcomes shape clinical guidelines and daily practice,1,2 we expect them to meet the highest standards 
of methodological quality and provide us with robust 
results.3,4  RCTs have benefitted from continuous im-
provement in methodological quality,5 especially in 
random sequence generation and allocation conceal-
ment, which have freed them from baseline confound-
ing.5–7 However, randomization does not eliminate 
differences that may arise between treatment groups 
during follow- up. After randomization, bias can arise 
when participants receive medical care in addition to 
the intervention of interest (cointerventions)6,8 if it is not 
provided equally to all treatment groups.8–11 
When one group receives more cointerventions than 
another, the RCT results may be compromised by bias.6–
8,11 This unequal distribution of cointerventions might be 
caused by a failure to adequately blind participants and/
or personnel.12–14 For example, if investigators know that 
a participant is receiving an active substance in a trial 
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designed to prevent myocardial infarction (eg, new an-
tidiabetic drugs), they might suggest that the participant 
take other medications that reduce cardiovascular risk 
(eg, statins). If a family doctor knows that a patient is 
not receiving the active substance, he or she might feel 
ethically bound to prescribe effective cointerventions.8 If 
cointerventions affect one group more than another, the 
results could be biased in either direction.6,8 To reduce 
the risk of bias, cointerventions should be reported in 
both unblinded (ie, open label) and in double- blind trials 
because blinding can be compromised during the course 
of even a double- blind RCT by, for example, drugs that 
are not adequately matched, specific side effects, or lab-
oratory investigations (such as lipid measurements).15–19 
It is difficult to measure unblinding in a double- blind 
RCT, but we can and should quantify its possible conse-
quences by reporting relevant cointerventions.13,16,17
Patients in cardiovascular trials often receive multiple 
treatments (eg, statins, antihypertensives, antiplatelets) 
beyond the studied medication, each of which could af-
fect outcomes, so cointerventions and in particular these 
comedications may play an important role in cardiovas-
cular RCTs, especially if unblinded.6,8,20,21 After several 
years without new potent drugs for cardiovascular pre-
vention, a number of large RCTs have demonstrated the 
benefit of recent drugs for cardiovascular prevention,22–27 
but in some there was risk that cointerventions were un-
balanced between study groups. We designed this sys-
tematic review to evaluate the quality of cointervention 
reporting in recently published RCTs with cardiovascular 
outcomes and to evaluate potential explanatory factors 
for reporting. We hypothesized that cointerventions would 
be more adequately reported in RCTs that were not fully 
blinded or otherwise at risk of bias because unbalanced 
cointerventions between trial arms may be more likely in 
these studies and could compromise their findings.
METHODS
Selection of Articles
We searched MEDLINE and EMBASE for RCTs evaluat-
ing pharmacological interventions on binary cardiovascu-
lar outcomes (fatal and/or nonfatal myocardial infarction, 
fatal and/or nonfatal stroke, mortality as well as compos-
ite outcomes) published in the 5 general medical journals 
with the highest impact factors (New England Journal 
of Medicine, Lancet, Journal of the American Medical 
Association, British Medical Journal, and Annals of 
Internal Medicine) between 2011 and 2019 (see Table S1 
for details of the search strategy). Our methods conform 
to the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses (PRISMA) statement for reporting 
systematic reviews and meta- analyses.28 The protocol is 
registered on PROSPERO (CRD42018106771). One re-
viewer (E.M.) screened all titles and abstracts, assessed 
the full text of eligible abstracts and articles, and identified 
relevant trials. Another investigator (L.A.) independently 
assessed the eligible abstracts. The data that support the 
findings of this study are available from the corresponding 
author upon request. 
Assessment of Included RCTs
The following information was extracted: study design 
(superiority versus noninferiority/equivalence trials), 
number of patients, type of intervention and compara-
tor, follow- up duration, outcomes, information concern-
ing methods of blinding of participants and personnel, 
blinding of outcome assessors, information about coin-
terventions, implementation of study treatment, adher-
ence to study treatment, cross- overs, statistical analysis 
conducted, and funding source (industry versus nonin-
dustry). Available information on cointerventions, blind-
ing of participants and/or personnel, adherence to 
study treatment, and statistical analysis was extracted 
CLINICAL PERSPECTIVE
What Is New?
• In this systematic review of major cardiovascu-
lar trials in 5 highly influential medical journals, 
cointerventions were inadequately reported in 
more than two-thirds of the trials, whereas the 
quality of reporting was not better among trials 
that were not fully blinded or at risk for bias.
What Are the Clinical Implications?
• Cointerventions should be systematically re-
ported in cardiovascular trials to assess the va-
lidity of the findings, particularly when trials are 
not fully blinded.
Nonstandard Abbreviations and Acronyms
OR odds ratio
RCT randomized clinical trial
RR relative risk 
CONSORT  Consolidated Standards of 
Reporting Trials
INR International normalized ratio
PRISMA  Preferred Reporting Items for 
Systematic Reviews and 
Meta-Analyses
SPORTIF  Stroke Prevention Using the Oral 
Direct Thrombin Inhibitor Ximelagatran 
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independently by 2 reviewers (E.M., L.A.). All available 
information was extracted from the original trial reports, 
supplementary material, and protocols (if available).
Definition of Cointerventions and Quality 
of Their Reporting
Two investigators (E.M., L.A.) independently assessed 
the cointervention reporting. Because we included RCTs 
with cardiovascular outcomes, we considered potential 
cointerventions whose modification has been shown to 
decrease cardiovascular risk (Box 1).8,29–34 We defined 
cointerventions as concomitant medications (statins, 
antihypertensives, antiplatelets) over follow- up (Box 1). 
In addition, diuretics, antidiabetics, and anticoagulants 
were also included in the definition of “cointervention” 
if these patients were included in the trials (ie, patients 
with heart failure, diabetics, or atrial fibrillation). We also 
defined 2 special categories of cointerventions in (1) 
RCTs where there was an index procedure after ran-
domization, in which case, in addition to concomitant 
medications (statins, antihypertensives, antiplatelets) 
over follow- up, procedural characteristics and peripro-
cedural medications between the groups would also be 
cointerventions29,30,33 (Box S1), and (2) in RCTs with an 
index procedure after randomization but with a follow-
 up of <1 month in which case cointerventions would be 
procedural characteristics and periprocedural medi-
cations without considering concomitant medications 
(statins, antihypertensives, antiplatelets; Box S1).29,30,33 
Although advice for smoking, diet, and physical activ-
ity are also effective cointerventions, they are difficult to 
quantify, are rarely assessed in the original studies, and 
are therefore not evaluated in the present study.
To evaluate the reporting quality of cointerventions in 
each RCT, cointerventions were judged as adequately re-
ported if the authors reported all cointerventions across 
trial arms (as described in Box 1) or if the authors explicitly 
stated that cointerventions did not differ between groups 
or gave indirect evidence that cointerventions did not dif-
fer between groups (eg, “there were no differences be-
tween groups in blood- pressure or cholesterol levels”) or 
that there were no cointerventions. We judged cointerven-
tions as inadequately reported if information in the article 
or supplement was incomplete (ie, partially reported) or 
missing (ie, not reported). Trials that did report cointer-
ventions were classed as either “balanced” if there were 
similar levels of cointerventions between both groups or 
“unbalanced” and were judged by 2 reviewers (E.M., L.A.) 
independently. Disagreements were resolved by consen-
sus in discussions that involved a third author (M.F.).
Assessment of Blinding and the risk of bias
We independently assessed the blinding of partici-
pants and/or personnel. We based our judgments 
about blinding participants and/or personnel on the 
Cochrane Collaboration risk of bias tool 2011 (Risk of 
bias 1.0) and instructions from Unverzagt et al (Table 
S2).35 We classified RCTs into having adequate blind-
ing or inadequate blinding. 
Two authors (E.M., L.A.) used the risk of bias 2.0 
tool to independently assess risk of bias caused by 
deviations from the intended interventions (effect of 
adhering to treatment),13 and classified RCTs as at high 
risk of bias, some concerns, or at low risk of bias. For 
our analysis, we grouped together RCTs judged as 
“some concerns” and RCTs judged as “at high risk of 
bias” and classed them all as “at risk of bias.”
In general, there was good agreement regarding 
the previous classifications: Cohen’s κ score for in-
terobserver variability was 0.84 for the reporting of 
cointerventions, 0.87 for blinding participants and/or 
personnel, and 0.76 for the RoB 2.0 assessment.
Statistical Analysis
We used descriptive statistics. Comparisons be-
tween groups were conducted using a chi- square 
test. We used univariable and multivariable logistic 
regressions to evaluate the association of reporting 
of cointerventions with blinding (adequately versus 
inadequately), risk of bias (trials at low risk of bias ver-
sus trials at risk of bias), funding (nonindustry funded 
versus industry funded), design (superiority versus 
noninferiority/equivalence), and duration of follow- up 
(≤1  month versus >1  month). Finally, in an analysis 
that was not prespecified in the protocol, we looked 
at RCTs that adequately reported cointerventions 
Box 1. Definition of Reporting
The reporting was adequate if all of the following elements were 
reported and inadequate if 1 or more elements were missing.* 
Cointerventions are defined as the following:
• Concomitant medications (statins, antihypertensives, 
antiplatelets) over follow-up.31,32,34†
Special conditions:
• If randomization before an index procedure‡ and follow-up 
>1 month: concomitant medications (statins, antihypertensives, 
antiplatelets†) over follow-up and procedural characteristics and 
periprocedural medications.29,30,33§
• If randomization before an index procedure‡ and follow-up 
<1 month: procedural characteristics and periprocedural 
medications.29,30,33§
*Information could be anywhere in main article or supplements. 
Cointerventions should be summarized by percentages or absolute 
number across groups or the authors should state explicitly in the 
main text that cointerventions did not differ across the groups.† 
Includes others depending on the condition under study, for 
example, antidiabetics in trials that included patients with diabetes 
mellitus or diuretics if heart failure or anticoagulants in trials that 
included patients with atrial fibrillation; see the detailed descriptions 
in Table S3.‡ Index procedures included percutaneous coronary–
angiography (n=18), cardiac surgery (n=5), surgery (n=2), and 
ablation (n=1); see the detailed description in Table S3.§ For more 
detailed descriptions of procedural characteristics/periprocedural 
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and explored the aforementioned factors for their 
association with balanced cointerventions between 
treatment arms using univariable logistic regression. 
P values were 2- sided and considered significant if 
P<0.05. For data management, analysis, and graph-
ics, we used Stata version 15.0. 
RESULTS
General Characteristics of Included RCTs
The literature search identified 1625 potentially eli-
gible reports. After screening titles and abstracts, 
we evaluated 149 full articles, of which 123 met the 
inclusion criteria (Figure S1). A detailed description 
of the excluded trials is provided in Table S3. Table 
S4 describes the main characteristics of the 123 in-
cluded RCTs: 83 (67.5%) were published in the New 
England Journal of Medicine; 27 (21.9%) had a nonin-
feriority/equivalence design; 94 (76.4%) were indus-
try funded; 45 (36.6%) examined antithrombotics or 
anticoagulants; 16 (13.0%) involved antidiabetics; 14 
(11.4%) involved antihypertensives; and 17 (13.8%) 
were lipid- modifying agents (Table S4). The primary 
end points of all trials were composite end points 
(Table S5), and all of the trials had blinded adjudica-
tion committees.
Reporting of Cointerventions
As seen in Table, cointerventions were inadequately 
reported in 87 of 123 RCTs (70.7%), with 56 (45.5%) 
providing no information on cointerventions and 31 
(25.2%) providing only partial information (Table). Table 
S5 provides detailed descriptions of the potential coint-
erventions in the protocols, all cointerventions reported 
and not reported, and the time points of reporting in 
each RCT. As seen in Table S6, the results remained 
similar in a stratified analysis based on medication cat-
egory. Assessing potential cointerventions at regular 
intervals, usually at each visit and the last visit, was 
often included in study protocols (Table S5). Protocols 
were not available in only 7 RCTs.
The Reporting of Cointerventions in Relation 
to Quality of Blinding and Risk of Bias
A total of 71 (57.7%) RCTs adequately blinded par-
ticipants and/or personnel, whereas 52 (42.3%) were 
inadequately blinded. Of the RCTs, 60 (48.8%) were 
at “low risk of bias”; 63 (51.2%) were “at risk of bias” 
(n=28, 22.8% as “some concerns”; n=35, 28.5% as “at 
high risk of bias”) because they deviated from planned 
interventions. Among the 52 trials with inadequate 
blinding of participants and/or personnel, 15 (28.9%) 
adequately reported cointerventions versus 21 (29.6%) 
in those with adequate blinding (P=0.93; Figure A). 
Among the 63 trials “at risk of bias,” 16 (25.4%) ad-
equately reported cointerventions versus 20 (33.3%) in 
those “at low risk of bias” (P=0.33; FigureB).
Factors Associated With Adequately 
Reporting Cointerventions
As seen in Table S7, the odds ratio (OR) in the univari-
able analysis for adequately reporting cointerventions 
was 1.04 (95% CI, 0.47–2.27) comparing adequately 
versus inadequately blinded trials, 1.47 (95% CI, 0.67–
3.21) comparing trials “at low risk of bias” versus trials 
“at risk of bias,” 2.06 (95% CI, 0.86–4.92) comparing 
non- industry- funded trials versus industry- funded tri-
als, 0.63 (95% CI, 0.26–1.55) comparing superiority 
trials versus noninferiority/equivalence trials, and 4.33 
(95% CI, 1.63–11.52) comparing trials with a follow- up 
≤1 month versus >1 month (Table S7). In multivariable 
analysis, only a follow- up of <1 month was associated 
with the adequate reporting of cointerventions (OR, 
3.63; 95% CI, 1.21–10.91; Table S7).
Factors Associated With Balanced 
Cointerventions
As seen in Table, among the 36 RCTs that adequately 
reported cointerventions, cointerventions were bal-
anced in 31 and unbalanced in 5 trials. All trials with 
unbalanced cointerventions were judged as inad-
equately blinded trials and were industry funded. As 
seen in Table S8, no other factor was associated with 
unbalanced cointerventions, even though the confi-
dence intervals were large.
DISCUSSION
In this systematic review of recent RCTs on cardio-
vascular outcomes, more than two- thirds of RCTs 
did not adequately report cointerventions. Reporting 
was not better among trials that were not fully blinded 
Table. Reporting of Cointerventions (n=123)
Variable* Sample, n (%)
Adequately reported 36 (29.3)
 Balanced 31/36 (86.1)
 Unbalanced 5/36 (13.9)
Partially reported 31 (25.2)
 Balanced 26/31 (83.9)
 Unbalanced 5/31 (16.1)
Not reported 56 (45.5)
*“Adequately reported” indicates if cointerventions of interest were 
reported across trial arms; “partially reported” indicates if only part of the 
information was provided; “not reported” indicates if there was no reporting 
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nor among RCTs at risk of bias in which the report-
ing of cointerventions would be particularly impor-
tant to assess the validity of their results. Adequate 
reporting of cointerventions was more common in 
trials that followed patients for <1  month, perhaps 
because cointerventions are easier to assess over a 
short follow- up.
Lack of blinding could lead to biased results through 
many different ways. Indeed, an association between 
lack of blinding and positive results has been shown, 
especially when the outcomes were subject to ascer-
tainment bias, that is, not “hard” outcomes.36 RCTs with 
inadequate blinding seem particularly at risk for unbal-
anced cointerventions,14 and reporting cointerventions 
is important because if they are unbalanced between 
treatment arms, they could introduce bias.6,8,11,13 In an 
earlier systematic review of 12 complementary/alterna-
tive medicine RCTs, cointerventions (use of analgesics) 
were reported in 7 of these studies, and it was shown 
that not blinding participants was associated with an 
1.55 increased risk (95% CI, 0.99–2.43) of receiving 
cointerventions.12 The lack of blinding and cointerven-
tions could also explain the differences in the effect 
sizes between SPORTIF III (Stroke Prevention Using 
the Oral Direct Thrombin Inhibitor Ximelagatran in 
Patients With Atrial Fibrillation),21 an open- label trial 
evaluating the effect of ximelagatran versus warfarin 
on strokes and systemic embolic events and SPORTIF 
V,20 a trial with otherwise similar design and end points 
with SPORTIF III, but double-blinded. Although the 
potential risk factors were well balanced across the 
treatment arms within each trial, the effect sizes were 
remarkably different between the 2 trials: SPORTIF III, 
primary event rate 1.6% per year with ximelagatran and 
2.3% per year with warfarin (relative risk [RR], 0.71; 95% 
CI, 0.48–1.07) versus SPORTIF V, primary event rate 
1.6% with ximelagatran per year and 1.2% with war-
farin per year (RR, 1.38; 95% CI, 0.91–2.10).  Outcome 
assessments were blinded in both trials. Indeed, in 
a pooled analysis of the 2 trials,37 it was shown that 
the differences between the trials could be attributed 
to differences in cointerventions such as statins and 
differences in other risk factors (eg, hypertension), in 
addition to less variability in international normalized 
ratio (INR) control in SPORTIF V,37,38 although ascer-
tainment bias cannot be excluded. In our review, the 
reporting of cointerventions was scarce in both RCTs 
with adequate and inadequate blinding, and we found 
no association between blinding and the reporting of 
cointerventions. The reasons for this could be that 
the reporting of cointerventions in cardiovascular tri-
als might have received less attention and/or be less 
standardized. Although the Consolidated Standards 
of Reporting Trials (CONSORT) statement recognizes 
that a lack of blinding may influence the use of coint-
erventions, subsequent reporting of cointerventions 
across groups is currently not mandatory.14 However, 
cointerventions are among the data required to be col-
lected in a Cochrane systematic review.13,39 
In cardiovascular medicine, cointerventions may 
be particularly important because participants usu-
ally receive many different treatments that could re-
duce cardiovascular risk and change cardiovascular 
outcomes.6,8 In the Women’s Health Initiative, which 
Figure. Proportion of trials reporting cointerventions according to blinding and risk of bias.
A, Proportion of trials reporting cointerventions according to blinding of participants and/or personnel (n=123). For the analysis, 
we grouped together the trials with no information on cointerventions and partial information and defined them as “not adequately 
reported”; P=0.93 for the comparison between groups. B, Proportion of trials reporting cointerventions according to risk of bias 
attributed to deviation of intended interventions (n=123). For the analysis, we grouped (1) trials with some concerns and at high risk 
of bias and defined them as “at risk of bias” attributed to the deviation of intended interventions and (2) trials with no information on 
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examined the effect of hormone therapy on cardiovas-
cular outcomes, the differential use of statins showed 
significantly different effects on coronary heart disease 
and stroke, confounding the results.6 A recently pub-
lished RCT on the effects of coronary computer tomog-
raphy on cardiovascular outcomes, which did not blind 
participants or personnel, found that the participants 
assigned to the intervention group were more likely to 
receive additional preventive treatments for cardiovas-
cular disease (statins, antihypertensives, antiplatelets).40 
In a double- blind RCT designed to test the effects of 
fenofibrate versus placebo on hard cardiovascular end 
points, 17% of the participants on placebo were also 
treated with statins versus 8% in the fenofibrate group, 
which may have caused the results to be biased toward 
the null.10 In many cardiovascular trials, depending on 
the type of intervention, the presence of cointerventions 
may reflect the effectiveness of the study treatment that 
occurs in a real world instead of a perfect hypothetical 
study scenario, and the blinding of participants and/or 
personnel may not always be possible. Nevertheless, 
as cointerventions may lead to an overestimation of 
treatment effect, this is of particular concern when the 
results of an RCT are used for the registration of a new 
drug. In addition, in this systematic review, we included 
RCTs with pharmacological interventions (and not sur-
gery or with devices), so that in these cases blinding is 
usually feasible.
This study has limitations. First, the results were 
limited to cardiovascular trials published in major 
medical journals, which represent a minority of pub-
lished clinical research. However, trials published in 
journals with high impact factors usually do better in 
terms of the quality of reporting,5 and previous meth-
odological reviews have used the same design.41 
Second, this study did not evaluate the reporting of 
cointerventions in medical fields other than cardio-
vascular. Third, the definition of which cointerven-
tions should be reported is (to some extent) arbitrary. 
We proposed a definition (Box  1) that was easy to 
apply, reflected by a high interobserver agreement 
(Cohen’s κ, 0.84).
CONCLUSIONS
More than two- thirds of recent major cardiovascular 
trials did not adequately report cointerventions. The 
quality of reporting was not better among trials that 
were not fully blinded or at risk of bias. Our review high-
lights the need for more standardized, systematic re-
porting of cointerventions in cardiovascular trials.
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Table S1. Literature search. 
(((("Annals of internal medicine"[Journal]) OR ("BMJ (Clinical research ed.)"[Journal]) OR 
("JAMA"[Journal]) OR ("Lancet (London, England)"[Journal]) OR ("The New England journal of 
medicine"[Journal])) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR 
randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] 
NOT (animals[mh] NOT humans[mh]))) AND (("Cardiovascular Diseases/drug therapy"[Mesh] OR 
"Cardiovascular Diseases/mortality"[Mesh] OR "Cardiovascular Diseases/prevention and control"[Mesh]) 
OR ("Myocardial Ischemia/drug therapy"[Mesh] OR "Myocardial Ischemia/mortality"[Mesh] OR "Myocardial 
Ischemia/prevention and control"[Mesh]) OR ("Myocardial Infarction/drug therapy"[Mesh] OR "Myocardial 
Infarction/mortality"[Mesh] OR "Myocardial Infarction/prevention and control"[Mesh]) OR ("Stroke/drug 
therapy"[Mesh] OR "Stroke/mortality"[Mesh] OR "Stroke/prevention and control"[Mesh]) OR 
("Cerebrovascular Disorders"[Mesh:noexp]) OR ("Ischemic Attack, Transient"[Mesh]) OR ("Intracranial 
Embolism and Thrombosis"[Mesh]) OR ("Intracranial Arteriosclerosis"[Mesh:noexp]))) NOT 
((comment[Publication Type]) OR (letter[Publication Type])) Filters: Publication date from 2011/01/01 to 
2019/04/11 
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Table S2. Adequate and inadequate blinding of participants and/or personnel. 
 *based on risk of bias due to lack of/insufficient blinding of participants and/or personnel of the Cochrane 
Collaboration risk of bias tool 2011 and on the basis of the instructions used from Unverzagt et al. (see ref. 
35)  
  
                                        Inadequate Adequate 
High Some concerns Low 
Open-label, Single-blind 
The method of masking was 
described and it was 
inappropriate (e.g. comparison of 





The authors stated that the study 
was double-blind but there was no 
adequate description in the text or 
in protocol (e.g. “matching 
placebo”) 
Treatments administered from 
care-givers  (i.v. i.m. injections): 
with no other description 
concerning the preparation (e.g. 
similar colour or matched, opaque 
syringes or bottles) 
Unblinding is possible (e.g. blood 
investigations, specific adverse 
effects) & no methods to avoid 
unblinding 
 
Both patients and caregivers 
were blinded 
Detailed description about how 
the blinding status was 
established and maintained  
(either in published paper of in 
protocol): matching placebo or 
adequate description  
No specific adverse effects or 
methods to avoid unblinding 
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Table S3. Description of 26 excluded studies. 
Author, y Reason for exclusion 
Anderson, 2016 (PMID:27161018) Primary outcome: death or disability define 
through modified Rankin scale 
He, 2014 (PMID: 24240777) Primary outcome: death and major disability 
through modified Rankin scale 
Kirchhof, 2012 (PMID: 22713626) Primary outcome: persistent atrial fibrillation or 
death 
Sandercock, 2012 (PMID: 22632908) Primary outcome: proportion of patients alive 
and independent, as defined by an Oxford 
Handicap Score  
Torres, 2014 (PMID: 25399731) Primary outcome: death, end-stage renal 
disease, or a 50% reduction from the baseline 
estimated GFR 
Sabatine, 2015 (PMID: 25773607) Other outcome;CV events assessed as 
prespecified exploratory analysis 
Robinson, 2015 (PMID: 25773378) 
 
Other outcome;CV events assessed as post hoc 
analysis  
Beckett, 2011 (PMID: 22218098) Extension of a randomised, clinical trial 
Bonow, 2011 (PMID: 21463153) Substudy  
De Boer, 2011 (PMID: 22077236) Extension of a randomised, clinical trial 
Gerstein, 2014 (PMID: 25088437) Analysis of data from other randomised, clinical 
trial 
Leonardi, 2016 (PMID: 27677503) Substudy 
Scirica, 2012 (PMID: 22932716) Substudy 
Wang, 2016 (PMID: 27348249) Substudy 
Williamson, 2016 (PMID: 27195814) Substudy/already included 
Zannad, 2015 (PMID: 25765696) Posthoc/already included 
Zoungas, 2014 (PMID: 25234206) Extension of a randomised, clinical trial 
Macdougall, 2013 (PMID: 23343062) Other outcome;CV events assessed only as 
safety 
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Cleland, 2011 (PMID: 21856481) 
 
Other outcome;CV events assessed only as 
safety 
Marchioli, 2013 (PMID: 23216616) Combination of pharmaceutical and non 
pharmaceutical treatments 
Ohman, 2017 (PMID: 28325638)  
 
Other outcome; CV events as exploratory 
outcome 
Anand, 2018 (PMID: 29132880) Substudy/already included 
Connolly, 2018 (PMID: 29132879) Substudy/already included 
Kudenchuch, 2016 (PMID: 27043165) Other outcomes 
Perkins, 2018 (PMID: 30021076) Other outcomes 
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Table S4. Trial characteristics (n=123). 
Variables Sample (n) (%) 
Journal  
New England Journal of Medicine 83 (67.5) 
Lancet 14 (11.4) 
Journal of the American Medical Association 24 (19.5) 
British Medical Journal 1 (0.8) 
Annals of Internal Medicine 1 (0.8) 
Type of comparator  
 Placebo only 72 (58.5) 
 Active (with the use of placebo) 34 (27.6) 
 Active only 14 (11.4) 
Standard of care (no treatment only)  3 (2.5) 
Trial Design  
Superiority 96 (78.1) 
Non-inferiority/equivalence 27 (21.9) 
Type of funding source  
Industry-sponsored  94 (76.4) 
Non-industry 29 (23.6) 
Type of intervention*   
Antihypertensives/diuretics/heart failure treatments 14 (11.4) 
Antithrombotics/anticoagulants 45 (36.6) 
Lipid-modifying medications 17 (13.8) 
Antidiabetics 16 (13.0) 
Antiinflammatory, antirheumatic, antineoplastic 12 (9.8) 
Cardiac therapy† 3 (2.4) 
Various‡ 16 (13.0) 
*Classified according to ATC Code; †includes antianginal treatment and antiarrhythmic medications 
‡includes antiobesity preparations, medications for the treatment of bone disease, vitamins, and combination 
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Table S5. Detailed characteristics of 123 included Randomized Clinical Trials and decriptions of 
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ACEI: angiotensive converting enzyme inhibitors, ACS: acute coronary syndrome, ARBs: Angiotensin II 
receptor blockers, CV: cardiovascular, FU: follow-up, GpIIb/IIa: Glycoprotein IIb/IIIa, HDL: high-densitiy 
cholesterol, HF: heart failure, LDL: low-density cholesterol, MACE: major adverse cardiac events, MI: 
myocardial infarction, NI: no information, NSAID: non-steroidal anti-inflammatory, PCI: percutaneous 









Table S6. Reporting of co-interventions according to medication category (n=123). 
Drug Reported (%,n) Not adequately 
reported (%,n) 
Overall (n=123) 29.3 (36) 70.7 (87) 
Antihypertensives/diuretics/heart 
failure (n=14) 
14.3 (2) 85.7 (12) 
Antithrombotics/anticoagulants 
(n=45) 
35.6 (16) 64.4 (29) 
Lipid-lowering treatment (n=17) 23.5 (4) 76.5 (13) 
Antidiabetics (n=16) 56.3 (9) 43.7 (7) 
Antiinflammatory, antirheumatic 
medication (n=12) 
16.7 (2) 83.3 (10) 
Cardiac treatments & various 
(n=19) 
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Table S7. Potential explanatory factors associated with the reporting of co-interventions (n=123). 
 Univariable analysis Multivariable analysis 




Blinding of participants and/or 
personnel* 
(ref: Inadequate blinding) 
      
Adequate blinding 1.04 0.47 to 
2.27 
0.93 0.99 0.41 to 
2.38 
0.99 
Risk of bias due to deviations of 
intended interventions† 
(ref: “At risk of bias”‡) 
      
“At low risk of bias” 1.47 0.67 to 
3.21 





      
Non-Industry 2.06 0.86 to 
4.92 
0.10 2.24 0.80 to 
6.25 
0.12 
Trial design  
(ref: Non-inferiority) 
      
Superiority 0.63 0.26 to 
1.55 




(ref: >1 month) 
      
 <1 month 4.33 1.63 to 
11.52 
0.003 3.63 1.21 to 
10.91 
0.02 
*according to risk of bias due to lack of blinding of participants and/or personnel (RoB 1.0);†risk of bias due 
to deviations of the intended interventions: effect of adhering to treatment (RoB 2.0); ‡”at risk of bias”: “some 
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Table S8. Factors associated with balanced co-interventions among RCTs with adequate reporting of 
co-interventions (n=36). 
                                                           Univariable analysis 
                                                                           OR 95%CI 
Blinding of participants and/or personnel† 
(ref: Inadequate blinding) 
  
Adequate blinding* Omitted*  
Risk of bias due to deviations of intended interventions 
(ref: “At risk of bias”‡) 
  






Trial design  
(ref: Non-inferiority) 
  
Superiority 5.14 0.71 to 37.15 
Follow-up 
(ref: >1 month) 
  
 <1 month 2.19 0.22 to 22.19 
† according to risk of bias due to lack of blinding of participants and/or personnel (RoB 1.0) ; ‡risk of bias due 
to deviations of the intended interventions: effect of adhering to treatment (RoB 2.0);”at risk of bias”: “some 
concerns” and “at high risk of bias”;*All trials with unbalanced co-interventions were judged as inadequately 
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Box S1. Detailed definition of procedural characteristics and periprocedural medications. 
  
- If the index procedure is cardiac surgery, minimum of procedural characteristics to be reported are: 
duration of aortic-cross clamping, on or off-pump surgery, duration of cardiac surgery. Minimum 
periprocedural medications to be reported are: antiplatelets, ACEIs/ARBs, statins, b-blockers (see ref. 29) 
- If the index procedure is percutaneous coronary angiography, minimum of procedural characteristics to 
be reported are: stents and type of stents (bare-metal stents, drug-eluting stents), balloon dilatation, 
arterial access site. –minimum of periprocedural medications to be reported are: Heparin or Bivalirubin, 
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searching 































Additional records identified 
through hand search 
(n = 3) 
Records after duplicates removed 
(n = 1625) 
Records screened 
(n = 1625) 
Records excluded based 
on title and abstract 
(n = 1476) 
Full-text articles assessed 
for eligibility 
(n = 149) 
Full-text articles excluded, 
with reasons 
(n = 26) 
- Not RCTs n = 12 
- Other outcomes n = 13 
Other comparisons n = 1  
 
Studies included in 
qualitative synthesis  
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